The use of asthma controller medications during pregnancy and the risk of gestational diabetes - 18/04/17
Doi : 10.1016/j.jaci.2016.06.031
Véronique Baribeau, MSc a, Marie-France Beauchesne, MSc a, b, Évelyne Rey, MD c, Amélie Forget, MSc c, Lucie Blais, PhD a, d 
a Faculté de pharmacie, Université de Montréal, Montreal, Quebec, Canada
b Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
c Centre hospitalier universitaire Sainte-Justine, Montreal, Quebec, Canada
d Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada
| This work was supported by a grant from the Canadian Institutes of Health Research (grant no. 126153). |
|
| Disclosure of potential conflict of interest: M.-F. Beauschesne has received grants and personal fees from Novartis and AstraZeneca. L. Blais has received grants from the Canadian Institutes for Health Research, AstraZeneca, and GlaxoSmithKline and has received personal fees from AstraZeneca and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 138 - N° 6
P. 1732 - décembre 2016 Retour au numéro
Article précédent
- A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria
- Jeffrey M. Harris, Christopher R. Cabanski, Heleen Scheerens, Divya Samineni, Mary S. Bradley, Colette Cochran, Petra Staubach, Martin Metz, Gordon Sussman, Marcus Maurer
- Bone marrow transplantation for MHC class I deficiency corrects T-cell immunity but dissociates natural killer cell repertoire formation from function
- Yifang Gao, Peter D. Arkwright, Rachel Carter, Angelica Cazaly, Rebecca J. Harrison, Alexandra Mant, Andrew J. Cant, Stephan Gadola, Tim J. Elliott, Salim I. Khakoo, Anthony P. Williams
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?